Key result
Captopril treatment in refractory heart failure increased cardiac index from 1.99 to 2.69 l/min/m and decreased pulmonary capillary wedge pressure.
Why the study?
Does oral captopril improve hemodynamics and clinical symptoms in patients with refractory heart failure?
Does oral captopril improve hemodynamics and clinical symptoms in patients with refractory heart failure?
Oral captopril provides significant and sustained hemodynamic and clinical improvement in patients with refractory heart failure without late vasodilator tolerance.
Answers are grounded in this paper and cite their sources.
Supports hemodynamic effects of captopril in refractory HF; hypothesis-generating and requires randomized confirmation.
10 patients suffering from refractory heart failure were treated with an oral angiotensin converting enzyme inhibitor captopril. The etiology of heart failure in 9 patients was related to ischemic heart disease, and to valvular heart disease in 1 patient. All patients experienced subjective improvement and feeling of well-being. The functional capacity improved to class II-IIB. Serial chest X-ray films showed improvement in pulmonary congestion. The time course of the hemodynamic effect appeared to 0.5-1.5 h after intake, and tended to disappear about 6 h later. The optimal dose of the drug achieving maximal hemodynamic benefit without excessive hypotension was 50 mg. Some of the patients exhibited a triphasic response. The cardiac index increased from 1.99 +/- 0.1 to 2.69 +/- 0.151/min/m (p less than 0.001), while pulmonary capillary wedge pressure decreased from 25.3 +/- 5.86 to 13.67 +/- 4.14 mm Hg (p less than 0.001). Mean peripheral arterial blood pressure decreased from 90.06 +/- 3.7 to 71.4 +/- 2.7 mm Hg. The total peripheral resistance decreased from 1,942 +/- 169 to 1,170 +/- 109 dyn X s X cm-5. The total pulmonary resistance decreased from 272.6 +/- 42.9 to 142.34 +/- 13.76 dyn X s X cm-5. Heart rate decreased from 83.4 +/- 10.9 to 70.8 +/- 10.14 bpm (p less than 0.01). During a 6-month follow-up period the beneficial clinical effects of captopril were sustained, without late vasodilator tolerance. 1 death, unrelated to captopril, occurred. 2 patients developed transient rash, and 1 experienced transient dysgeusia.
No takes yet. Share an insight, caveat, or question.
Abinader et al. (2008) studied Refractory heart failure (n=10). Captopril was evaluated on Cardiac index (p=<0.001). Captopril treatment in refractory heart failure increased cardiac index from 1.99 to 2.69 l/min/m and decreased pulmonary capillary wedge pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: